☰

Patrick P. Ng, Ph.D. - Publications

Affiliations: 
2005 University of California, Los Angeles, Los Angeles, CA 
Area:
Molecular Biology
Tree Info Similar researchers PubMed Report error

10 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2012 Ng PP, Jia M, Patel KG, Brody JD, Swartz JR, Levy S, Levy R. A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity. Proceedings of the National Academy of Sciences of the United States of America. 109: 14526-31. PMID 22875703 DOI: 10.1073/Pnas.1211018109  0.355
2012 Torchia JA, Ng PP, Chen H, Kohrt HE, Marabelle A, Alizadeh AA, Levy R. Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy Blood. 120: 3713-3713. DOI: 10.1182/blood.v120.21.3713.3713  0.346
2011 Patel KG, Ng PP, Levy S, Levy R, Swartz JR. Escherichia coli-based production of a tumor idiotype antibody fragment--tetanus toxin fragment C fusion protein vaccine for B cell lymphoma. Protein Expression and Purification. 75: 15-20. PMID 20851769 DOI: 10.1016/J.Pep.2010.09.005  0.369
2009 Patel KG, Ng PP, Kuo CC, Levy S, Levy R, Swartz JR. Cell-free production of Gaussia princeps luciferase--antibody fragment bioconjugates for ex vivo detection of tumor cells. Biochemical and Biophysical Research Communications. 390: 971-6. PMID 19852937 DOI: 10.1016/J.Bbrc.2009.10.087  0.367
2009 Ng PP, Jia M, Virrueta A, Patel K, Swartz JR, Levy S, Levy R. Novel Anti-CD19/Idiotype Bispecific Diabody Vaccine for B-Cell Lymphoma. Blood. 114: 2712-2712. DOI: 10.1182/Blood.V114.22.2712.2712  0.358
2007 Daniels TR, Ng PP, Delgado T, Lynch MR, Schiller G, Helguera G, Penichet ML. Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Molecular Cancer Therapeutics. 6: 2995-3008. PMID 18025284 DOI: 10.1158/1535-7163.Mct-07-0330  0.555
2006 Ng PP, Helguera G, Daniels TR, Lomas SZ, Rodriguez JA, Schiller G, Bonavida B, Morrison SL, Penichet ML. Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood. 108: 2745-54. PMID 16804109 DOI: 10.1182/Blood-2006-04-020263  0.607
2006 Helguera G, Dela Cruz JS, Lowe C, Ng PP, Trinh R, Morrison SL, Penichet ML. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors. Vaccine. 24: 304-16. PMID 16125282 DOI: 10.1016/J.Vaccine.2005.07.073  0.506
2005 Asai T, Trinh R, Ng PP, Penichet ML, Wims LA, Morrison SL. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery. Biomolecular Engineering. 21: 145-55. PMID 15748688 DOI: 10.1016/J.Bioeng.2004.10.001  0.625
2002 Ng PP, Dela Cruz JS, Sorour DN, Stinebaugh JM, Shin SU, Shin DS, Morrison SL, Penichet ML. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 99: 10706-11. PMID 12149472 DOI: 10.1073/Pnas.162362999  0.521
Show low-probability matches.